Table 3.
Prognostic values of baseline body mass index at diagnosis: Cox models
| Univariate analysis | Multivariable analysis* | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Overall survival | ||||
| Categorical BMI | ||||
| Overweight vs. normal | 1.65 (1.18–2.31) | 0.004 | 1.23 (0.85–1.79) | 0.27 |
| Obese vs. normal | 1.85 (1.34–2.55) | < 0.001 | 1.15 (0.79–1.65) | 0.47 |
| Continuous BMI, per 5 kg/m2 | 1.18 (1.10–1.28) | < 0.001 | 1.09 (0.99–1.20) | 0.073 |
| Breast cancer-specific survival | ||||
| Categorical BMI | ||||
| Overweight vs. normal | 1.86 (1.15–3.03) | 0.012 | 1.72 (1.01–2.93) | 0.045 |
| Obese vs. normal | 1.74 (1.08–2.81) | 0.023 | 1.36 (0.79–2.33) | 0.27 |
| Continuous BMI, per 5 kg/m2 | 1.11 (0.99–1.25) | 0.079 | 1.01 (0.87–1.16) | 0.92 |
| Disease-free survival | ||||
| Categorical BMI | ||||
| Overweight vs. normal | 1.65 (1.25–2.18) | < 0.001 | 1.30 (0.96–1.76) | 0.094 |
| Obese vs. normal | 1.67 (1.28–2.19) | < 0.001 | 1.09 (0.80–1.48) | 0.59 |
| Continuous BMI, per 5 kg/m2 | 1.15 (1.08–1.23) | < 0.001 | 1.04 (0.96–1.13) | 0.37 |
*Adjusted for age, race, Carlson comorbidity index, tumor stage, histologic grade, estrogen receptor, progesterone receptor, Her2, radiotherapy, hormonal therapy, and chemotherapy in delayed entry Cox models
Abbreviations: BMI body mass index, HR hazard ratio, CI confidence intervals